Company
Headquarters: Heze, China
Employees: 1,110
CN¥4.38 Billion
CNY as of Jan. 1, 2025
US$600.1 Million
| Company | Market Cap (USD) |
|---|---|
| Novo Nordisk | $622.07 B |
| Vertex Pharmaceuticals Incorporated | $113.24 B |
| CSL Limited | $95.75 B |
| Regeneron Pharmaceuticals, Inc. | $76.33 B |
| Marinomed Biotech AG | $56.13 B |
| Company | Market Cap (USD) |
|---|---|
| Lilly | $689.42 B |
| Novo Nordisk | $622.07 B |
| UnitedHealth Group | $487.54 B |
| Johnson & Johnson | $353.05 B |
| AbbVie | $301.60 B |
Shandong Sito Bio-technology Co., Ltd. researches and develops new steroid hormones, intermediates, and derivatives. Its products include 9a-hydroxyandrostenedione, 17a-hydroxyprogesterone, 17a-hydroxy progesterone derivatives, anecort acetate, dexamethasone epoxy hydrolysate, progesterone intermediate, opener, tetraene, androstenedione, ketal, acid removal, 3-ketal, and betamethasone epoxy hydrolyzate, as well as 1,4-androstenedione. The company was founded in 2002 and is based in Heze, China.
Top 1-year algo backtest: +327.04%
$10,000 in March 2024 would now be $42,704 by following this algorithm daily at market close.
Use AI to boost your investing & swing trading, now!
Try Disfold DeepFinance FREE
Shandong Sito Bio-technology Co. Ltd has the following listings and related stock indices.
Stock: SZSE: 300583 wb_incandescent